MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
This quarter, MindMed (MNMD) will begin a Phase 2a trial to see if its non-hallucinogenic ibogaine formulation (MM-110) can treat opioid withdrawal.
In preclinical research, MM-110 showed “multi-day reductions in opioid self-administration” after a single dose.
In the Phase 1 trial, MM-110 was found to be safe and well-tolerated at varying doses. Some participants received two 325 mg doses on a single day while others received a 90 mg dose twice daily for 7 days.
Let’s see what Phase 2 reveals!